Notice of UC San Diego Health CEO Maysent's Five-Year Review

In accordance with University of California – Regents Policy 7702 requiring a Leadership Development Assessment to be conducted once every five years, I am initiating a formal five-year review of Patty Maysent, Chief Executive Officer for UC San Diego Health (CEO Health).

As CEO of UC San Diego Health, Maysent manages the region's only academic health system, comprising UC San Diego Medical Center, Jacobs Medical Center, Shiley Eye Institute and Sulpizio Cardiovascular Center, as well as other primary and specialty practices located throughout Southern California. She oversees a $2 billion annual operating budget and more than 9,000 employees.

In consultation with the Academic Senate and Campus and Health Leadership, I have appointed a committee to conduct a review of CEO Maysent’s performance and to provide to me a report of its findings. The review committee members are:

Theodore Chan, Professor and Chair, Emergency Medicine (Review Chair)
Edward Ball, Professor and Chair, Medicine
Judith Bruner, Chief Ethics and Compliance Officer
Maripat Corr, Professor, Medicine; Associate Dean, Academic Affairs
Don Kikkawa, Professor and Vice-Chair, Ophthalmology
Michael M. Madani, Professor and Chief, Cardiovascular and Thoracic, Surgery
Jyoti Mayadev, Professor and Assistant Vice Chair, Development Therapeutics, Radiation Medicine
Kristin Mekeel, Professor, Clinical Surgery; Chief of Transplantation and Hepatobiliary Surgery
Becky R. Petitt, Vice Chancellor for Equity, Diversity and Inclusion
Amber Sanchez, Associate Clinical Professor, Medicine
Robert Weinreb, Professor and Chair, Ophthalmology

The charge to the committee is to evaluate CEO Maysent’s performance in the full spectrum of leadership responsibilities for UC San Diego Health, including but not limited to the following areas: leadership ability, decision-making ability, administrative and managerial skills, and representational ability.

Some of the critical features to be addressed in the review include CEO Health Maysent’s leadership in advancing patient care, financial health and sustainability of UC San Diego Health; evolving the UC San Diego Health system for serving its patients, staff, faculty, students and community; supporting the diversity of the institution; fostering interdisciplinary relations and expanding collaborative opportunities; and working with external and professional communities.

In the coming weeks, the review committee will solicit comments from individuals who have direct and specific knowledge of her performance and contributions. The review committee will strive to ensure the confidentiality of all respondents. Individuals wishing to provide input may also contact Review Chair Chan at ceohealthreview@ucsd.edu. All comments are due by Friday, July 15, 2022. Thank you in advance for your input.

Pradeep K. Khosla
Chancellor